OrthoPediatrics (NASDAQ:KIDS) Issues Quarterly Earnings Results

OrthoPediatrics (NASDAQ:KIDS) released its quarterly earnings data on Tuesday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02), FiscalAI reports. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The company had revenue of $72.66 million during the quarter, compared to analyst estimates of $68.50 million.

OrthoPediatrics Stock Down 0.8%

KIDS traded down $0.20 during midday trading on Tuesday, hitting $23.82. 372,144 shares of the company’s stock traded hands, compared to its average volume of 180,831. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.78 and a quick ratio of 2.17. The company has a market cap of $621.94 million, a PE ratio of -14.18 and a beta of 0.99. The stock’s fifty day simple moving average is $23.04 and its 200-day simple moving average is $19.38. OrthoPediatrics has a one year low of $14.42 and a one year high of $26.74.

Insiders Place Their Bets

In related news, Director David R. Pelizzon sold 302,369 shares of OrthoPediatrics stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $21.01, for a total value of $6,352,772.69. Following the completion of the sale, the director owned 6,201,764 shares of the company’s stock, valued at approximately $130,299,061.64. The trade was a 4.65% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Squadron Capital Llc sold 302,369 shares of the stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $21.01, for a total transaction of $6,352,772.69. Following the transaction, the insider directly owned 6,201,764 shares in the company, valued at $130,299,061.64. The trade was a 4.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 2,100,000 shares of company stock valued at $46,747,931 over the last ninety days. Corporate insiders own 32.50% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on KIDS shares. Truist Financial upgraded shares of OrthoPediatrics to a “hold” rating in a report on Thursday, October 1st. Weiss Ratings upgraded OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 5th. BTIG Research reissued a “buy” rating and set a $29.00 price objective on shares of OrthoPediatrics in a research report on Monday, September 14th. Needham & Company LLC lifted their price objective on OrthoPediatrics from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Piper Sandler restated an “overweight” rating and issued a $25.00 target price (up from $22.00) on shares of OrthoPediatrics in a research note on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

About OrthoPediatrics

OrthoPediatrics Corp. is a medical device company focused exclusively on developing and commercializing orthopedic products for children. The company designs implants, instruments and related technologies intended to address the distinct anatomical and clinical needs of pediatric patients, including those with congenital conditions, traumatic injuries and musculoskeletal disorders.

Its product portfolio covers pediatric trauma and deformity correction, scoliosis, limb reconstruction, sports medicine and other specialized orthopedic procedures.